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Abstract 26 
 GII.4 noroviruses (NoVs) are the primary cause of epidemic viral acute gastroenteritis. 27 
One primary obstacle to successful NoV vaccination is the extensive degree of antigenic 28 
diversity among strains.  The major capsid protein of GII.4 strains is evolving rapidly, resulting 29 
in the emergence of new strains with altered blockade epitopes.  In addition to characterizing 30 
these evolving blockade epitopes, we have identified monoclonal antibodies (mabs) that 31 
recognize a blockade epitope conserved across time-ordered GII.4 strains.  Uniquely, blockade 32 
potency of mabs that recognize the conserved GII.4 blockade epitope was temperature sensitive 33 
suggesting that particle conformation may regulate functional access to conserved, blockade, 34 
non-surface-exposed epitopes.  To map conformation regulating motifs, we used bioinformatics 35 
tools to predict conserved motifs within the protruding domain of the capsid and designed mutant 36 
VLPs to test the impact of substitutions in these motifs on antibody cross-GII.4-blockade.  37 
Charge substitutions at residues 310, 316, 484 and 493 impacted blockade potential of cross-38 
GII.4 blockade mabs, with minimal impact on blockade of mabs targeting other, separately 39 
evolving, blockade epitopes.  Specifically, residue 310 modulated antibody blockade temperature 40 
sensitivity in tested strains.  These data suggest access to the conserved GII.4 blockade antibody 41 
epitope is regulated by particle conformation, temperature, and amino acid residues positioned 42 
outside of the antibody binding site.  The regulating motif is under limited selective pressure by 43 
the host immune response and may provide a robust target for broadly reactive NoV therapeutics 44 
and protective vaccines.  45 
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Importance 46 
In this study, we explored the factors that govern norovirus cross-strain antibody 47 
blockade.  We found that access to the conserved GII.4 blockade epitope is regulated by 48 
temperature and distal residues outside of the antibody binding site.  These data are most 49 
consistent with a model of NoV particle conformation plasticity that regulates antibody binding 50 
to a distally conserved blockade epitope.  Further, antibody “locking” of the particle into an 51 
epitope accessible conformation prevents ligand binding, providing a potential target for broadly 52 
effective drugs.  These observations open lines of query into the mechanisms of human NoV 53 
entry and uncoating, fundamental biological questions that are currently unanswerable for these 54 
non-cultivatable pathogens. 55 
56 
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Introduction 57 
 Noroviruses (NoVs) are the primary cause of severe acute viral gastroenteritis (1).  In the 58 
United States alone, the annual NoV disease burden is estimated to be 2 billion dollars and 5,000 59 
quality adjusted life years (2).  Globally, NoV-associated deaths are estimated at 200,000 per 60 
year (3).  Usually, disease severity is modest, but morbidity and mortality rates, particularly 61 
among the young, elderly, and immune-compromised are increasingly apparent (4-14).  An 62 
effective vaccine would benefit not only these highly susceptible populations but also military, 63 
childcare, healthcare and food industry personnel.  The primary obstacles to development of an 64 
effective NoV vaccine are the large number of antigenic variants, viral evolution, and an 65 
incomplete understanding of the components of protective immunity.  A monovalent NoV 66 
vaccine based on Norwalk virus virus-like particles (VLPs) has demonstrated to be safe and 67 
effective at mitigating the risk of NoV illness and infection (15, 16).  Although an important first 68 
step, additional studies that include NoV strains of more epidemiological relevance are needed to 69 
address the fundamental immunogenetic questions surrounding NoV susceptibility and 70 
protection from infection.  71 
 Strains from the GII.4 genotype cause 70-80% of norovirus outbreaks including four 72 
pandemics in the last 15 years.  Strain US95/96 (GII.4.1997) mitigated the pandemic during the 73 
mid-1990’s (17, 18), followed by the Farmington Hills strain (GII.4.2002) (19), the Hunter strain 74 
(GII.4.2004) (20-22), and the Minerva 2006b strain (GII.4.2006) (10, 21, 23).  Although the 75 
number of documented outbreaks did not significantly increase, GII.4.2006b was subsequently 76 
replaced by the global circulating strain New Orleans (GII.4.2009) (1, 24). In 2012, the newly 77 
emerged Sydney strain (GII.4.2012) (25, 26) became the predominant circulating NoV strain, 78 
worldwide.  This pattern of emergent strain replacement of a circulating strain followed by 79 
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periods of stasis is indicative of epochal evolution and results in new GII.4 strains with altered 80 
antigenicity and ligand binding profiles (27, 28).  Importantly, of the NoVs studied, epochal 81 
evolution appears to be restricted to GII.4 NoV strains over the past 25 years. 82 
 Currently, there is no validated cell culture model for human norovirus cultivation.    As 83 
members of the Caliciviridae family, NoVs contain positive-sense, single stranded RNA 84 
genomes of about 7.5 kb.  Currently, there are five identified genogroups.  Almost all human 85 
NoV infections are caused by strains from Genogroups (G) I and GII.  Each of these genogroups 86 
is further subdivided into 9 and 21 different genotypes, respectively, based primarily on the 87 
amino acid sequence of the major capsid protein encoded by ORF 2 (29).  When ORF2 is 88 
expressed in vitro an abundance of the major capsid protein is produced (30).  Monomers of the 89 
major capsid protein first form dimers; then ninety dimers self-assemble into icosahedral virus-90 
like particles (VLPs) that are morphologically and antigenically indistinguishable from native 91 
virions (31).  The capsid protein itself is divided into three structural domains. The shell domain 92 
(S) forms the core of the particle and the protruding domain, which is divided into two 93 
subdomains; P1(residues 226-278 and 406-530) forms a stalk that extends away from the central 94 
core supporting the protruding subdomain 2 (P2, residues 279-405) (31).  The P2 subdomain is 95 
the most surface-exposed region of the particle and has been shown to interact with potential 96 
neutralizing/blockade antibodies and carbohydrate binding ligands, such as  synthetic histo-blood 97 
group antigens (HBGAs), human saliva, and pig gastric mucin (28, 32-36).  In the GII.4 strains, 98 
residues of the P2 subdomain are under selective pressure by the host immune response; this 99 
pressure drives viral evolution resulting in antigenic drift and escape from herd immunity (28, 100 
35, 37).  The lack of a cell culture system for NoV propagation prompted  us to develop an in 101 
vitro surrogate neutralization assay, or antibody “blockade” assay, that measures the capacity of 102 
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an antibody to block binding of a VLP to a carbohydrate ligand (28, 35, 38, 39). Importantly, the 103 
blockade assay has been verified by other groups as a surrogate neutralization assay in infected 104 
chimpanzees (40) and Norwalk virus-challenged people (15, 41).  The surrogate neutralization 105 
“blockade” assay has been critical in mapping evolving GII.4 blockade antibody epitopes in 106 
strains antigenically too similar to be differentiated by enzyme immunoassay (EIA) (28, 42). 107 
 In addition to antigenic drift, several other viral factors correlate with new GII.4 strain 108 
emergence, including strain recombination (43) and polymerase fidelity (44, 45).  Unfortunately, 109 
the absence of a standard infection model outside of humans, limits the possibility to study these 110 
mechanisms of viral immune evasion in depth.   To date, only antigenic drift has been shown to 111 
directly impact the effectiveness of the human immune response to mitigate NoV infection.  112 
Using anti-GII.4 NoV human monoclonal antibodies (human mabs) we have mapped evolving 113 
GII.4 blockade epitopes (46, 47).  Changes in these epitopes not only correlate with new strain 114 
emergence but also with loss of antibody blockade activity providing direct evidence that new 115 
GII.4 strains are serial human herd immunity escape variants.  Many groups have used 116 
bioinformatics tools to predict potential GII.4 antibody epitopes (20, 27, 28, 48, 49).  By 117 
coupling a large panel of anti-NoV monoclonal antibodies (mabs) with molecular genetic 118 
approaches we have validated three evolving GII.4 blockade epitopes.  Epitope A (residues 294, 119 
296-298, 368 and 372) is highly variable and changes with each new GII.4 strain emergence (35, 120 
36, 46, 47).  Epitope D (residues 393-395) is an evolving blockade epitope that also modulates 121 
HBGA binding of GII.4 strains providing mechanistic support for the observed correlation 122 
between epitope escape from herd immunity and altered HBGA binding (28, 47, 49).  Epitope E 123 
(residues 407, 412 and 413) is a confirmed GII.4.2002 Farmington Hills-specific blockade 124 
epitope (36). 125 
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 We have also described a GII.4-conserved, conformation-dependent blockade epitope 126 
recognized by human mab NVB 71.4 (47).  Although this epitope is conserved across GII.4 127 
strains that circulated between 1987 and 2012, NVB 71.4 does not have equivalent blockade 128 
capacity for all GII.4 VLPs, suggesting the antibody binds to a complex epitope comprised of 129 
both conserved and variable residues.  NVB 71.4 has diagnostic and therapeutic potential and 130 
mapping of the epitope recognized by human mab NVB 71.4 may provide a target for widely 131 
protective NoV drugs or vaccine design. 132 
In this study, we demonstrate that antibody NVB 71.4 cross-blockade and access to the 133 
conserved GII.4 blockade epitope is regulated by particle conformation, temperature and amino 134 
acid residues positioned outside of the antibody binding site.  Strategies to control particle 135 
conformation changes will inform NoV immunogen presentation in VLP-based vaccines and 136 
therapeutics. 137 
138 
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Materials and Methods 139 
 140 
Virus-like particles.  Synthetically derived (Bio Basic INC, Amherst, NY) epitope-engineered 141 
or outbreak strain ORF2 genes were inserted directly into the VEE replicon vector for the 142 
production of virus replicon particles (VRPs), as described (35, 42).  Bac-GII.4.2009 (New 143 
Orleans) VLPs were the kind gift of Dr. Jan Vinje, Centers for Disease Control and Prevention, 144 
Atlanta, GA and produced by expression in the baculovirus system and purified by cesium 145 
chloride gradient.  Uranyl acetate stained VLPs were visualized by transmission electron 146 
microscopy (TEM).  Scale bars (100 nm) are included in all micrographs for size reference.  Of 147 
note, sequences used to produce VLPs were identified from stool samples from multiple infected 148 
individuals.  Although irregular particles are occasionally seen in all VLP preparations regardless 149 
of the vector expression platform (28, 50), ORF2 proteins that self-assemble into plentiful ~40 150 
nm spherical particles that retain robust binding to conformation-dependent monoclonal 151 
antibodies and carbohydrate ligands are considered validated for further studies. 152 
 153 
Monoclonal Antibodies.  The characteristics of the antibodies used in this study have been 154 
previously published except GII.4.2002.G5.  Details are described in (47) for the human mabs 155 
and in (35, 51) for the mouse epitope A mabs.  NVB 71.4 is a broad GII.4 blockade human mab 156 
isolated from a healthy blood donor.  GII.4.2002.G5 is a mouse mab generated by 157 
hyperimmunization with GII.4.2002 VLPs, as described (36).  This antibody is now 158 
commercially available from Maine Biotech (MAB227P).  Fabs were obtained by papain 159 
cleavage using papain immobilized on beaded agarose resin (30 IU/mg) (Pierce) followed by 160 
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HiTrap protein-A (GE Healthcare) and size-exclusion chromatography (Superdex 200 from GE 161 
Healthcare).  162 
 163 
Blocking Of Binding (BOB) Assay. For experiments using human polyclonal serum, human 164 
mabs were purified on protein A or G columns (GE Healthcare) and biotinylated using the EZ-165 
link NHS-PEO solid-phase biotinylation kit (Pierce). The competition between polyclonal serum 166 
antibodies and biotinylated human mabs for binding to immobilized VLPs (1 μg/ml) was 167 
measured by EIA. Briefly, plasma samples were added to GII.4.1997 or GII.4.2006-coated plates 168 
at different dilutions. After 1 hour, biotinylated human mab was added at a concentration 169 
corresponding to 80% of the maximal OD level, and the mixture was incubated at room 170 
temperature for 1 hour. Plates were then washed with PBS-0.05% Tween-20 and bound 171 
biotinylated humab was detected using AP-labeled streptavidin (Jackson Immunoresearch). The 172 
percentage of inhibition was tested in duplicates and calculated as follows: (1í[(OD sampleíOD 173 
neg ctr) / (OD pos ctríOD neg ctr)])×100. BD80 value was calculated by interpolation of curves 174 
fitted with a 4-parameter nonlinear regression.  For screening donor plasma samples and human 175 
mab blocking of binding of mouse mabs, the binding titers to respective coated VLPs were 176 
determined by EIA by measuring the dilution required to achieve 50% maximal binding (EC50) 177 
as previously described (47).  EIA plates were coated at 0.25 μg/ml VLP for human mab BOB of 178 
mouse mab assays.  179 
 180 
Predicting Epitopes.  Guided by the empirical data observed for NVB 71.4 that indicated a 181 
conserved GII.4 epitope was present, we reasoned that differential binding noted between GII 182 
and GII.4 strains could be used to refine the search for a conserved region of the GII.4 capsid 183 
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sequence. Representatives of the capsid amino acid sequences of GII strains and GII.4 strains 184 
(28)  from 1974 to 2012 were aligned using ClustalX version 2 (52) and the amino acid residues 185 
that were conserved among all GII capsid sequences and all GII.4 capsid sequences were 186 
mapped onto the GII.4.2004 (PDB accession: 3JSP) (53) crystal structure to identify areas that 187 
were conserved among all GII and all GII.4 capsid proteins. The original analysis was performed 188 
using the crystal structure for GII.4.1997 as the distances in the structure used for making the 189 
epitope prediction would be more reliable than in a homology model. The ERK and EHNQ 190 
motifs were identified as regions that were conserved among GII noroviruses, and highly 191 
conserved among GII.4 viruses. E316, R484, and K493 (ERK) and E488, H501, N522 and Q523 192 
(EHNQ) were identified as conserved residues in these regions that carried a charge and had 193 
exposed side chains that protruded. These sites were targeted for mutagenesis using the rationale 194 
that preserving the charge of these residues would preserve the structural components necessary 195 
for VLP formation.  Of note, epitope location predictions are based on VLP structures, not native 196 
virion structures. 197 
 198 
VLP-Carbohydrate Ligand-Binding Assay. 199 
EIA plates were coated with 10 ȝg/ml Pig Gastric Mucin (PGM) for 4 hours and blocked over 200 
night at 4ºC in 5% dry milk in PBS-0.05% Tween-20 before the addition of increasing 201 
concentrations of VLP.  Bound VLP were detected by a rabbit anti-GII.4 norovirus polyclonal 202 
sera made from hyperimmunization with a cocktail of GII.4.1987, GII.4.2002, GII.4.2006 and 203 
GII.4.2009 VLPs, followed by anti-rabbit IgG-HRP (GE Healthcare) and color developed with 204 
1-Step Ultra TMB ELISA HRP substrate solution (Thermo-Fisher).  Each step was followed by 205 
washing with PBS-0.05% Tween 20 and all reagents were diluted in 5% dry milk in PBS-0.05% 206 
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Tween-20,  pH 6.9.  VLP binding to PGM is stable between pH 6.3 and 8.1, agreeing with 207 
previously published results (54).  All incubations were done at room temperature.  PGM at10 208 
μg/ml is a saturating concentration and cannot distinguish carbohydrate affinities between VLPs 209 
but does give maximum binding potential of the entire panel of GII.4 VLPs.  Half maximum 210 
binding (EC50) values were calculated using sigmoidal dose response analysis of non-linear data 211 
in GraphPad Prism 6 (www.graphpad.com).  Percent of maximum binding was compared to the 212 
mean OD 450 nm of 12 μg/ml VLP.  213 
 214 
VLP-Carbohydrate Ligand-Binding Antibody Blockade Assay. 215 
For blockade assays, PGM-coated plates were prepared as described above.  VLPs (0.25 ȝg/ml) 216 
were pretreated with decreasing concentrations of test mab for 1 hour before being added to the 217 
carbohydrate ligand–coated plates for 1 hour.  Wash steps and bound VLP were detected as 218 
described above.  The percent control binding was defined as the binding level in the presence of 219 
antibody pretreatment compared to the binding level in the absence of antibody pretreatment 220 
multiplied by 100. Antibody-VLP and VLP-PGM incubations were done at room temperature or 221 
37żC, as described for each figure.  All other incubations were done at room temperature.  222 
Blockade data were fit using sigmoidal dose response analysis of non-linear data in GraphPad 223 
Prism 6.  EC50 values were calculated for antibodies that demonstrated blockade of at least 50% 224 
at the dilution series tested. Monoclonal antibodies that did not block 50% of binding at the 225 
highest dilution tested were assigned an EC50 of 2X the assay upper limit of detection for 226 
statistical comparison.  EC50 values between VLPs were compared using the One-way ANOVA 227 
with Dunnett posttest, when at least three values were compared or a student's T test when only 228 
two values were compared. A difference was considered significant if the P value was <0.05.  Of 229 
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note, VLP concentrations in blockade assays are in the low nanomolar range and therefore 230 
cannot discriminate between antibodies with sub-nanomolar affinities. Antibody-VLP 231 
interactions were validated for compliance with the law of mass action by preforming blockade 232 
assays of GII.4.1997 and GII.4.2006 at 0.25, 0.5, 1 and 2 μg/ml VLP.  EC50 values for antibody 233 
blockade varied less than 2-fold (1 dilution) between any combination of VLP concentration 234 
tested, indicating that under the test conditions, antibody is in excess to the VLP and the tenants 235 
of the law of mass action are met for the antibody-VLP binding (data not shown).  Blockade 236 
assays using human type A or B saliva as the source of carbohydrate ligand were performed as 237 
described (55) with 0.5 μg/ml VLP at room temperature and 37°C. 238 
Antibody relative affinity measurements.  Antibody Kd measurements were done as previously 239 
described (56) at room temperature and 37°C.  Serial dilutions were tested in duplicate in at least 240 
two independent experiments for each temperature.  Briefly, EIA plates were coated with 0.25 241 
μg/ml VLP in PBS, blocked, and incubated with serial dilutions of test antibody.  Bound 242 
antibody was detected by anti-human IgG-HRP and color developed as described above.  Kd 243 
values were calculated using one-site specific binding equation in GraphPad Prism 6.  Kd values 244 
were validated by repeating the above assay at a range of VLP concentrations. 245 
VLP-Protein A gold staining.  VLPs were incubated with 5 μg/ml human mab at 37°C 246 
followed by 1/100 dilution of Protein A conjugated to 10 nm gold particles at room temperature, 247 
absorbed onto prepared grids, stained with 2% Uranyl acetate and visualized by TEM.  Staining 248 
specificity was validated by counting fifty fields of the negative control (VLP minus human IgG 249 
plus Protein A-gold).  Only one gold particle was observed near a VLP in the fifty negative 250 
control fields. 251 
252 
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Results 253 
Antibodies to conserved NoV epitopes are rarely detected in human serum samples.  To 254 
estimate the fraction of antibodies specific for conserved GII.4 epitopes in the overall serum 255 
antibody response, one hundred serum samples collected from healthy individuals were assayed 256 
for ability to block binding of human mabs NVB 61.3 and NVB 71.4 in a blockade of binding 257 
(BOB) assay (57, 58).  Both human mabs recognize a broad panel of antigenically-diverse, 258 
epidemiologically-significant GII.4 NoV strain VLPs by EIA but only NVB 71.4 blocks VLP-259 
ligand interactions (47).  When tested against GII.4.1997 (Figure 1A) or GII.4 2006 (Figure 260 
1B), three sera were able to compete with NVB 61.3 binding by more than 80% while the 261 
remaining did not show significant inhibition, in spite of variable binding to tested VLPs (Figure 262 
1, right column of each panel). Eighteen serum samples competed with NVB 71.4 binding to 263 
GII.4.1997 and six sera could compete for binding to GII.4.2006 by more than 80% (Figure 1).  264 
These data indicate that antibodies to GII.4 conserved epitopes may be rare in human serum 265 
samples even if the binding titers to the tested VLPs are high for the majority of the sera (EC50 266 
value reported in the right column of each panel).  267 
  268 
The conserved GII.4 blockade epitope is likely not surface exposed and antibody access to 269 
the epitope is regulated by particle conformation.  To characterize the epitope recognized by 270 
NVB 71.4 we compared the profile for NVB 71.4 blockade of a time-ordered panel of GII.4 271 
VLPs representing circulating GII.4 strains from 1987 through 2012.  As shown previously (47), 272 
blockade curves had relatively shallow slopes (range 0.68-0.92) (Figure 2A).  These data 273 
suggest that access of NVB 71.4 to the conserved blockade epitope may be restricted under the 274 
test conditions.  Therefore, we repeated the blockade assay for NVB 71.4 against the panel of 275 
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GII.4 VLPs at 37oC to increase the probability of the VLPs adopting a conformation more 276 
favorable for antibody binding during the incubation time (59).  Incubation at 37oC significantly 277 
increased the blockade capacity of NVB 71.4 for the panel of GII.4 VLPs (Figure 2B).  Further, 278 
the blockade curves demonstrated steep slopes (range 1.1-2.8) with complete blockade reached at 279 
antibody saturation for each VLP.  In agreement with previous findings (47), NVB 71.4 did not 280 
block each GII.4 VLP equivalently at room temperature or 37oC.  Incubation at the higher 281 
temperature resulted in significantly less antibody needed for blockade of GII.4.1987 (21.4-fold 282 
less), GII.4.1997 (35.4-fold less), GII.4.2002 (5.0-fold less), GII.4.2006 (10.5-fold less), 283 
GII.4.2009 (6.9-fold less) and GII.4.2012 (9.9-fold less) (Figure 2C).  Incubation at 37oC did not 284 
broaden the number of strains blocked by NVB 71.4, as the higher temperature did not allow 285 
blockade of any non-GII.4 VLPs tested (data not shown), in agreement with previous findings at 286 
room temperature (47). Temperature dependent NVB 71.4 blockade activity was confirmed with 287 
alternative ligand sources human type A and type B saliva (data not shown).  As demonstrated 288 
for PGM, all of the tested VLPs were blocked at lower concentrations of NVB 71.4 at 37oC 289 
compared to RT.  Although the temperature effect was retained across ligand sources, the degree 290 
of temperature effect varied by both GII.4 VLP and between the three types of ligand, in 291 
agreement with earlier reports (28, 47). 292 
In contrast, EC50 titers for blockade of surface epitopes A and D were only minimally 293 
impacted by temperature. GII.4.2006 blockade by human mabs that bind to surface-exposed 294 
epitopes A and D required 1.4 and 1.3-fold less antibody, respectively, for 50% blockade of 295 
binding at 37oC compared to room temperature (data not shown).  Although the mean EC50 titers 296 
for blockade of epitopes A and D are significantly different between room temperature and 37oC, 297 
the fold difference between the values reflects less than one two-fold serial dilution.  These data 298 
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indicate that unlike epitopes A and D, the conserved blockade epitope recognized by NVB 71.4 299 
may not be readily accessible on the viral particle at all times, resulting in regulated antibody 300 
access under tested conditions.  301 
In our screen of over 100 mouse mabs against GII.4 VLPs, we have identified only one 302 
mab with broad GII.4 blockade activity and this cross-blockade was temperature dependent 303 
(Figure 3).  In agreement with NVB 71.4 findings, GII.4.2002.G5 mouse mab did not block each 304 
GII.4 VLP equivalently at room temperature or 37oC.  Incubation at the higher temperature 305 
resulted in less antibody needed for blockade of GII.4.1987 (46-fold less), GII.4.1997 (8.5-fold 306 
less), GII.4.2002 (9.2-fold less), GII.4.2006 (10.2-fold less), GII.4.2009 (3.6-fold less) and 307 
GII.4.2012 (3.9-fold less).  Incubation at 37oC did not broaden the number of strains blocked 308 
(data not shown).  The varied degrees of blockade between different GII.4 VLPs suggests that 309 
the epitope GII.4.2002.G5 recognizes is composed of both residues that are conserved and 310 
variable across the GII.4 panel, as observed for NVB 71.4 (Figure 2). 311 
Viruses and virus-like particles are dynamic structures and the degree of structural 312 
flexibility is temperature sensitive and can be influenced by host factors (59-61).  While this 313 
study is the first to show that VLPs produced from VEE replicons likely adopt different 314 
conformations, to our knowledge no studies have demonstrated that viruses or VLPs assembled 315 
in the baculovirus insect cell system which functions at 27-28°C, are similarly dynamic.  316 
Therefore, we compared GII.4.2009 VLPs produced in the baculovirus-based insect system 317 
(27°C) and the VEE-based mammalian system (37°C) for antibody blockade at room 318 
temperature and 37°C.  Importantly, the primary nucleotide sequence of both GII.4.2009 capsid 319 
constructs is identical (GenBank accession number ADD10375).  For both mammalian and 320 
insect cell-produced GII.4.2009 VLPs, blockade of surface epitope A was efficient and not 321 
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temperature sensitive ( 1.3-fold less antibody needed for 50% blockade) (Figure 4A).  322 
Unexpectedly, NVB 71.4 blockade was also not temperature sensitive (1.3-fold more antibody at 323 
37°C) for the insect cell-produced VLPs, compared to 6.9-fold less antibody needed at 37°C for 324 
the mammalian cell produced VLP.  Further, NVB 71.4 blockade of GII.4.2009 VLP produced 325 
in insect cells required 29.3-fold less antibody for 50% blockade at room temperature and 3.2-326 
fold less at 37°C compared to GII.4.2009 VLPs produced in mammalian cells (0.1133 and 327 
0.1503 μg/ml compared to 3.322 at room temperature and 0.4817 μg/ml at 37°C (Figures 4B 328 
and 2 and (47)).  GII.4.2002.G5 needed 93-fold less antibody at room temperature and 19-fold 329 
less at 37°C for 50% blockade for GII.4.2009 VLPs produced in insect cells compared to 330 
mammalian cells (0.0843 and 0.1173 μg/ml compared to 7.8 μg/ml  at room temperature and 331 
2.177 μg/ml at 37°C (Figures 4C and 3).  This lack of temperature effect on Bac-GII.4.2009 332 
blockade was maintained when B saliva was used as the ligand source and when NVB 71.4 Fab 333 
fragments were used for the blocking antibody (data not shown).  These data support other study 334 
findings suggesting that factors outside of the capsid sequence can modify VLP antigenicity in 335 
subtle ways and support the hypothesis that antibody access to the conserved GII.4 blockade 336 
epitope is regulated by temperature and likely particle conformation. 337 
Prediction of a conserved GII.4 motif with epitope-like features.  Using the crystal structure 338 
of GII.4.2004 P domain dimer (PDB accession: 3JSP) (53), conserved and variable amino acids 339 
were mapped onto the P domain dimer surface. A region that was highly conserved among GII.4 340 
norovirus strains was identified on the side of the P domain dimer (Figures 5A and B), within 341 
the P1 subdomain, interior to the exposed surface of the P2 subdomain, and distal to the 342 
carbohydrate binding pockets that correlate with binding differences to NVB 71.4 (Figures 5B 343 
and C).  This region contained several conserved amino acids in an area large enough to 344 
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represent a potential antibody binding site (>10002 Å), including charged amino acids at 345 
positions E316, R484, and K493 (post-1997 GII.4 numbering) (Figure 5C). These amino acids 346 
were named the ERK motif (Figure 5C).  The ERK motif is highly conserved among GII.4 347 
strains that circulated between 1987 and 2012 and was predicted to be either a binding site for or 348 
a regulator of NVB 71.4 binding.  In addition, amino acid position 310 was identified as a site of 349 
variation among contemporary GII.4 epidemic strains (2009 and 2012) that was proximal to the 350 
highly conserved region containing the ERK motif (Figure 5D).  351 
 Conservation of the ERK motif and its sub-surface P1 location indicated that changes in 352 
these residues could be detrimental to viral particle structure or stability.  Therefore, to evaluate 353 
the impact of the ERK motif on antibody blockade activity we designed mutant VLPs in the 354 
GII.4.2006 backbone that conserved the residue charge but changed the residue side chain 355 
length.  The GII.4.2006.ERK clone contains substitutions E316D, R484K and K493R (Figure 356 
6A).  For comparison, we designed an additional P1 domain mutant based on a conserved GII 357 
antibody epitope recently published (62).  GII.4.2006.EHNQ contains mutated residues E488D, 358 
H501K and N522Q and Q523N (post-1997 GII.4 numbering) (Figure 6A).  The GII.4.2006.ERK 359 
substitutions did not notably alter particle structure as measured by electron microscopy 360 
visualization of ~40 nm spherical particles and ligand binding ability similar to GII.4.2006.  361 
However, microscopic visualization of GII.4.2006.EHNQ mutant revealed numerous irregular 362 
structures but no ~40nm spherical particles. Corresponding to the lack of particle integrity, this 363 
mutant was unable to bind carbohydrate ligand (Figure 6B and C).  Having failed VLP 364 
manufacturing quality control, no additional studies were performed with mutant 365 
GII.4.2006.EHNQ.  366 
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The GII.4 conserved ERK motif impacts NVB 71.4 and GII.4.2002.G5 blockade capacity 367 
with little impact on temperature sensitivity.  As the substitutions made within 368 
GII.4.2006.ERK retained ligand binding activity, we evaluated the impact of these residue 369 
changes on the blockade potency of NVB 71.4, GII.4.2002.G5, and antibodies to surface 370 
exposed epitopes.  ERK substitutions resulted in minimal increases in blockade ability for both 371 
epitope A and D antibodies (1.3-fold less antibody needed for 50% blockade at 37oC compared to 372 
room temperature for both human mabs, data not shown).  However, the ERK motif substitutions 373 
resulted in complete loss of blockade potency of NVB 71.4 at room temperature.  Blockade 374 
potency was restored at 37oC (2.519 μg/ml), although significantly more antibody was needed 375 
for blockade compared to GII.4.2006 (4.1-fold more antibody) (Figure 7A).  Similarly, 376 
GII.4.2002.G5 did not block GII.4.2006.ERK at room temperature but gained limited blockade 377 
potency at 37°C (11.43 μg/ml) (Figure 7B).  However, significantly more antibody was needed 378 
for blockade of GII.4.2006.ERK compared to GII.4.2006 even at the elevated temperature (3.6-379 
fold more).  Further, blockade of GII.4.2006 and GII.4.2006.ERK with NVB 71.4 Fab fragments 380 
was more potent (lower EC50 value) but similarly temperature sensitive compared to NVB 71.4 381 
IgG.  Notably, the EC50 values were 2.1-fold different at room temperature (1.758 verses 0.8052) 382 
and 1.4-fold different at 37°C (0.1807 compared to 0.1259), indicating that with the smaller 383 
epitope-binding molecule, the ERK residues do not effect antigenicity (Figure 7C). Further, 384 
ERK substitutions negatively impact blockade potency for both conserved epitope antibodies but 385 
do not negate the compensatory effect of incubating at higher temperature, indicating that the 386 
ERK residues may be affecting antibody access to the epitope instead of the antibody binding 387 
strength for the epitope.  388 
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Quantitative EIAs (56) further indicate that ERK residue substitutions do not affect 389 
antibody affinities.  Based on the differences in blockade titer, if the ERK substitutions were 390 
primarily affecting antibody affinity we would expect a 10-fold change in functional affinity for 391 
NVB 71.4 at room temperature and a 4-fold change at 37°C.  However, there is less than a two-392 
fold difference (one serial dilution) between antibody functional affinities (Kd values) of NVB 393 
71.4, GII.4.2002.G5 and epitope D human mab for GII.4.2006 and GII.4.2006.ERK VLPs 394 
between room temperature and 37°C (Table 1), clearly indicating that the ERK motif is not the 395 
antibody biding site. 396 
Residue 310 modulates antibody blockade potency and temperature sensitivity.  397 
Dominant GII.4 strains circulating between 1987 and 2006 conserved an asparagine at residue 398 
310.  With the emergence of GII.4.2009, N310 became S310.  Subsequently, GII.4.2012 replaced 399 
the serine at 310 with an aspartic acid (Figure 8B).  To investigate the role of residue 310 in 400 
GII.4 VLPs, we first developed mutated VLPs that exchanged the 310 residue between 401 
GII.4.2009 and 2012 (Figure 9A). These substitutions did not notably alter particle structure as 402 
measured by electron microscopy visualization and ligand binding ability (Figure 9B and C) or 403 
blockade by epitope A or D human mabs (data not shown).  In these constructs the ERK motif 404 
was unchanged.  For both NVB 71.4 and GII.4.2002.G5, exchange of residue 310 between 405 
GII.4.2009 and GII.4.2012 resulted in an exchange of potency and temperature sensitivity 406 
phenotypes (Figure 10A and B and dta not shown).  GII.4.2009.S310D blockade potency 407 
decreased (2 and 4.1-fold) and temperature sensitivity increased 10.5 and 12-fold for NVB 71.4 408 
and GII.4.2002.G5, respectively.  Conversely, GII.4.2012.D310S blockade potency increased 2.7 409 
and 3.2-fold and temperature sensitivity decreased 4.6 and 3.1-fold for each antibody.  NVB 71.4 410 
Fab had modestly increased potency at room temperature (1-2.8 fold) for the 310 mutant VLPs 411 
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and the blockade was less temperature sensitive (2.4-8.0 fold) compared to wildtype, indicating 412 
that the smaller molecule has better access to the epitope. 413 
 To evaluate the interplay between residue 310 and the ERK motif, we created VLP 414 
GII.4.2009.NERK containing both the S310D and ERK substitutions (S310D, E316D, R484K 415 
and K493R) (Figure 9A).  This VLP is called NERK, instead of SERK because of the asparagine 416 
found at 310 in the GII.4 VLPs from 1987-2006.  Interestingly, combining the 310 and ERK 417 
residue changes in the GII.4.2009 backbone resulted in a VLP that was similarly blocked as 418 
GII.4.2009 for NVB 71.4 but required 4.1-fold more GII.4.2002.G5 for 50% blockade.  Of note, 419 
for both IgGs and NVB 71.4 Fab the NERK substitutions reduced the advantage of incubating at 420 
higher temperature by ~50% compared to wildtype VLP blockade.  As there was less than a 2-421 
fold difference in Kd values for NVB 71.4 or GII.4.2002.G5 binding to GII.4.2009 and 422 
GII.4.2009.NERK at room temperature or 37oC (data not shown) it is unlikely that NERK forms 423 
the antibody epitope but instead that 310 and the ERK residues together form a regulating 424 
network.  Blockade by anti-epitope A and D human mabs was unaffected by the 310 or NERK 425 
residue mutations indicating that the substitutions were specifically targeting the conserved 426 
blockade epitopes and not causing global particle disturbances (data not shown).  These data 427 
indicate in multiple GII.4 backbones that residue 310 has a subtle effect on blockade potency at 428 
room temperature and a more significant effect on temperature sensitivity of the conserved 429 
blockade epitope.  Comparison of the effect of serine verses aspartic acid at position 310 430 
indicates better access to the epitope because of variation in regulating residues reduces the 431 
effect of incubating at higher temperature. 432 
NVB 71.4 VLP-ligand interaction blockade is not explained by particle disassembly or 433 
steric hindrance.  To explore the mechanisms of NVB 71.4 blockade we stained GII.4.2009 and 434 
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GII.4.2009.NERK VLPs with NVB 71.4 and epitope A human mabs and Protein A gold particles 435 
and observed antibody labeled VLPs by negative stain electron microscopy (Figure 11).  Both 436 
NVB 71.4 and the epitope A human mabs labeled intact VLPs, indicating that the antibody-437 
induced lack of ligand binding was not the result of antibody-mediated particle disassembly or 438 
that NVB 71.4 preferentially binds to disassembled capsid protein.  To evaluate if NVB 71.4 439 
binding to sub-surface sites altered the particle surface in a way that was undetectable by EM but 440 
rendered the particle unamenable to interactions at the surface, antibody blockade of binding 441 
competition assays were performed using antibodies to surface-exposed, conformation-442 
dependent epitope A and sub-surface, conformation-dependent NVB 71.4 (Figure 12).  When 443 
VLP coated plates were pre-incubated with an epitope A human mab, binding of a mouse epitope 444 
A mab was reduced.  The epitope A human mab blocked 50% of binding of a mouse epitope A 445 
mab at 0.7325 μg/ml for GII.4.1997 and 0.1419 μg/ml for GII.4.2006.  Binding of the epitope A 446 
human mab did not affect binding of the mouse mab GII.4.2002.G5 for either VLP.  Likewise, a 447 
strain mismatched epitope A human mab did not affect binding of either the mouse epitope A or 448 
GII.4.2002.G5 antibody binding for either VLP.  Conversely, pre-incubation of the VLP with 449 
NVB 71.4 did not affect binding of the mouse epitope A mabs but decreased binding of 450 
GII.4.2002.G5.  NVB 71.4 human mab blocked 50% of binding of mouse GII.4.2002.G5 at 451 
0.0982 μg/ml for GII.4.1997 and 0.1913 μg/ml for GII.4.2006.  Combined, these data indicate 452 
that VLPs bound by NVB 71.4 retain conformation and spatial flexibility for interaction with 453 
molecules that bind to the particle surface, suggesting neither particle disassembly nor steric 454 
hindrance is likely to explain NVB 71.4 blockade activity. 455 
456 
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Discussion 457 
The extensive burden of NoV disease on both pre and post-industrialized nations 458 
warrants World Health Organization support for development of a NoV vaccine.  A new GII.4 459 
strain has emerged every 3-4 years since 2002 and the newly emergent strain, with altered 460 
blockade epitopes, has quickly spread globally thorough immunologically-naive populations, 461 
highlighting a significant hurdle to successful NoV vaccination regimens.  Extensive work has 462 
documented the antigenic changes in epitope A that correlate with GII.4 strain emergence (35, 463 
36, 42, 46) providing a possible surveillance target for NoV monitoring.  Epitope D remained 464 
fairly static until GII.4.2012 Sydney mutations resulted in a loss of blockade activity by human 465 
mab NVB 97 (46).  While the biological relevance of both epitopes A and D has been confirmed 466 
with human mabs, the natural variation within these epitopes makes them difficult targets for 467 
antigen-based vaccine design. 468 
In comparison, blockade epitopes conserved among multiple epidemiologically important 469 
strains of virus, including herd-immunity escape mutants, provide potential targets for broadly 470 
protective vaccines and the antibodies that recognize these epitopes provide potential diagnostic 471 
and therapeutic reagents [50].  Recently, Hansman et al. (62) reported a linear GII NoV 472 
conserved antibody epitope that is exposed transiently by proposed changes in particle 473 
conformation.  This antibody was not tested for blockade capacity and is unlikely to recognize 474 
the GII.4 conformation-dependent conserved blockade epitope. The conserved GII.4 blockade 475 
epitopes recognized by human mab NVB 71.4 and mouse mab GII.4.2002.G5 likely overlap but 476 
are not identical as NVB 71.4 can compete with GII.4.2002.G5 binding, but NVB 71.4 has a 477 
higher blockade capacity and a different preferential blockade pattern across a panel of time-478 
ordered GII.4 VLPs.   479 
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The concept of viral capsids as dynamic structures that can assume different 480 
conformations is a well-established assumption in virology.  Herein, we map specific residues 481 
that mediate possible conformation subsets, which may be important for manufacturing NoV 482 
VLP based vaccines.  Despite identifying residue changes that affect blockade capacity of NVB 483 
71.4 and GII.4.2002.G5, we have not identified the epitope(s) that actually bind these mabs.  For 484 
both mabs, Kd and EC50 values were less than 2-fold different between GII.4.2006 and 485 
GII.4.2006.ERK and while ERK substitutions decrease blockade potency of the antibodies they 486 
do not eliminate the impact of elevated temperature on blockade.  Further, blockade of 487 
GII.4.2006 and GII.4.2006.ERK with NVB 71.4 Fab fragments reduces the effect of ERK 488 
substitutions while maintaining the effect of temperature on blockade.  These data clearly 489 
indicate that the effect of the ERK motif on mab blockade is not the result of loss of antibody 490 
binding to the epitope but instead suggest that ERK regulates antibody blockade capacity by 491 
regulating functional access to the epitope itself.  Previous work with polio virus (60) and West 492 
Nile virus (59) has shown that temperature effects particle dynamics or “breathing”  and 493 
subsequently antibody access to non-surface epitopes.  In both cases, at 37°C viruses are 494 
dynamic structures reversibly exposing internal antibody epitopes that are concealed at 25°C.  495 
Elegant studies with flaviviruses have carefully dissected the impact of residue changes, time, 496 
and temperature on monoclonal antibody neutralization (59, 63).  Similar to observations 497 
reported here, for many antibodies the effect was less than one log of neutralization titer.  Given 498 
the limited impact of ERK changes on temperature dependence of blockade, the ERK domain 499 
may lie near the antibody epitopes and influence blockade through an allosteric effect by altering 500 
the environment surrounding the epitopes or it may conformation-shield the epitope from the 501 
antibody. Why GII.4 NoVs occlude the conserved blockade epitope at room temperature but not 502 
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37°C is unknown but suggests that the epitope may be essential for infection and thus need to be 503 
exposed in the host (37°C), but is also susceptible to degradation and thus needs to be protected 504 
in the external environment where infection is not a viable option.  In the absence of a feasible 505 
infection model and GII.4 molecular clone, it is not possible to evaluate the relationship between 506 
different particle conformations (epitope accessible verses not accessible) and infectious virus.  507 
Blockade of residue 310 mutant VLPs indicate that 310 is a conformational regulator of access to 508 
the conserved blockade epitopes in multiple GII.4 backgrounds.  Comparing blockade of 509 
GII.4.2009 (S310), GII.4.2006 (N310), GII.4.2012 (D310), GII.4.2009.S310D and 510 
GII.4.2012.D310S VLPs, all in the context of the conserved ERK motif, supports a role for 511 
residue 310 in accessibility of the conserved blockade epitope.  Our data suggest that an aspartic 512 
acid at position 310 limits access to the epitope more than a serine.  Our structural analyses did 513 
not have sufficient resolution to explain the impact of different amino acids at position 310.  514 
Importantly, residue 310 exchanges did not completely recapitulate the wild type VLP blockade 515 
temperature phenotype, suggesting that either additional residues likely impact antibody access 516 
to the conserved GII.4 blockade epitope or residues within the actual epitope vary somewhat 517 
between the two strains.  Detailed crystallography studies of antibody-bound particles are needed 518 
to answer these fundamental questions. 519 
 Although the mechanisms of antibody blockade of VLP-carbohydrate binding are not 520 
known the correlation between antibody blockade titer and protection from infection and illness 521 
has been documented (15, 41).  The location of the ERK motif on the underside of the P domain,  522 
suggests that NVB 71.4 and GII.4.2002.G5 do not block VLP-ligand interaction by providing a 523 
physical barrier between the VLP and carbohydrate ligand, as is proposed for antibodies to the 524 
surface-exposed epitopes A, D and E (Figures 13) (35, 36, 47).  This hypothesis is supported by 525 
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observations that NVB 71.4 binding to VLP does not disrupt binding of antibody to surface 526 
epitope A and that antibody Fab fragments retain blockade activity for GII.4 VLPs.  Blockade of 527 
VLP-ligand binding is also not a function of antibody-mediated particle disassembly or the result 528 
of the antibody binding to already disassembled particles, as mab staining of NVB 71.4-labeled 529 
VLPs only identified intact particles.  Instead, we hypothesize that NVB 71.4 and GII.4.2002.G5 530 
likely block VLP-ligand interaction by altering VLP conformation, i.e. by positioning the VLP in 531 
an epitope-accessible conformation (full antibody access to the conserved blockade epitope) that 532 
is unfavorable for ligand binding (Figure 14).  Whether ligand binding is dependent upon the 533 
VLP being in an epitope-restricted conformation (limited antibody access to the conserved 534 
blockade epitope) or if the actual transition between epitope-accessible and epitope-restricted is 535 
key for ligand binding is yet to be determined. These results mimic well defined neutralization 536 
processes for antibodies that recognize conformation-shielded, conserved neutralization epitopes 537 
in a diverse group of RNA viruses, including the E protein DI domain of West Nile Virus (59, 538 
64),  the gp120 component of the Env protein of HIV (65, 66) and the Hemagglutinin stem of 539 
Influenza Virus type A (66, 67).  Interestingly, each of these epitopes have residues in structural 540 
motifs that are either directly or indirectly involved in viral entry and fusion processes, further 541 
suggesting that the antibodies described here may neutralize GII.4 NoV strains by blocking the 542 
virus entry/uncoating mechanisms, although this is speculative. 543 
Further study of GII.4.2009 VLP produced in an insect cell expression system at lower 544 
temperature provides support for the relationship between viral conformation and antibody 545 
blockade.  Blockade of Bac-GII.4.2009 by NVB 71.4 and GII.4.2005.G5 is potent and not 546 
temperature dependent, suggesting that the native conformation of GII.4.2009 in this system 547 
highly favors the “epitope-accessible" form.  Conversely, GII.4.2009 VLPs made in a 548 
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mammalian expression system at 37°C require more antibody for blockade and the blockade is 549 
temperature sensitive indicating that the particle assembly conditions can effect particle 550 
structure, epitope access and, subsequently, blockade potency for NVB 71.4 and GII.4.2002.G5.  551 
Even though the primary nucleotide sequence of the exogenous gene is identical in the insect cell 552 
vector and mammalian cell vector, multiple factors could explain the difference between the two 553 
GII.4.2009 VLPs including post-translational protein processing, although none of the NoV 554 
major capsid proteins studied to date have been found to be modified after production, 555 
temperature of particle assembly, and particle purification and storage conditions; all factors that 556 
could impact particle structure.  Previous detailed studies of Norwalk virus VLPs produced in 557 
insect cells indicate that these VLPs undergo structural changes at high temperature (>50°C) and 558 
pH (>8) but are stable at the pH and temperatures of the blockade assay (68).  How these studies 559 
with Norwalk virus VLPs relate to the GII.4 VLPs studied here is unknown as others have shown 560 
Norwalk and GII.4 VLPs have different pH-dependent ligand binding characteristics (54).  In 561 
agreement with (54), pH did not affect ligand binding of GII.4 VLPs we tested (data not shown).  562 
Although temperature effects both kinetics and affinities of molecular interactions, temperature 563 
alone is unlikely to explain the difference, as VLPs made by infecting mammalian cells at 30°C 564 
with GII.4.2009 VRPs resulted in VLPs with the same antibody blockade potency and 565 
temperature dependence as VLPs made at 37°C from the same VRP.  These data suggest that 566 
factors outside of the primary nucleotide sequence, including the host cell, may affect particle 567 
formation in subtle ways and antibody neutralization potential in significant ways.  If the 568 
observed differences between the two GII.4.2009 VLPs studied here is the direct result of VLP 569 
production in the baculovirus vector system, this is key information for manufacturing of the 570 
baculovirus produced-VLP NoV vaccine currently in phase I study, as computational studies on 571 
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human papillomavirus suggest that limiting structural fluctuations should produce better vaccine 572 
immunogens (69). While the Bac-GII.4.2009 VLPs clearly allow better antibody access to the 573 
epitopes for NVB 71.4 and GII.4.2002.G5 compared to VLPs made using VRP in the 574 
mammalian system, it seems likely that other sub-surface blockade epitopes will be less 575 
accessible on the Bac-GII.4.2009 VLP.  Detailed crystallography studies of antibody-bound 576 
particles are needed to answer these fundamental questions about VLP structure and how it 577 
impacts cross-strain blockade antibody responses.  However, all of the crystallography studies on 578 
NoV VLPs have been done on baculovirus or other non-mammalian cell culture derived proteins.  579 
Given the observations presented here the field should consider evaluating VLPs produced in 580 
additional mammalian based systems.   581 
Antibodies to conserved GII.4 NoV blockade epitopes have important therapeutic and 582 
vaccine potential. Human mab NVB 71.4 could be administered prophylactically for acute or 583 
chronic illness (70).  More importantly, the antibody could be used as a probe for antigen 584 
panning to identify the conserved blockade epitope.  The epitope could possibly then 585 
subsequently be genetically engineered to have better access within an immunizing VLP.  The 586 
supposition that locking the VLP in an epitope-accessible conformation prevents ligand binding 587 
suggests that a drug that could similarly lock viral conformation could be an effective broad 588 
based NoV treatment, as has been described for rhinovirus treatment with WIN compounds (71).  589 
Further, these observations open lines of query into the mechanisms of human NoV entry and 590 
uncoating, presenting fundamental biological questions that are currently unanswerable for these 591 
non-cultivatable pathogens. 592 
593 
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 Figure Legends 825 
Figure 1.  Antibodies to conserved NoV epitopes are rare in human plasma. The ability of 826 
human serum samples (n=100) to block binding of human mabs was evaluated using a Blockade 827 
of Binding (BOB) assay. Shown is the reciprocal plasma dilution that blocks 80% binding (BD80) 828 
of a conserved GII non-blockade epitope antibody (NVB 61.3) and a conserved GII.4 blockade 829 
epitope antibody (NVB 71.4) to GII.4.1997 (Panel A) and GII.4.2006 (Panel B) VLPs. Each 830 
symbol represents a different individual. BD80 values <40 were scored as negative. Total serum 831 
IgG binding to GII.4.1997 and GII.4.2006 was determined by EIA. Reciprocal EC50 values are 832 
shown (right column Panel A and B). ŸSera competing for binding of NVB 61.3; • Sera 833 
competing for binding of NVB 71.4; ∗ Donor source of NVB 61.3 and 71.4.  834 
 835 
Figure 2.  Access of NVB 71.4 to the conserved GII.4 blockade epitope is temperature 836 
dependent. NVB 71.4 was assayed for ability to block the interaction of a panel of time-ordered 837 
GII.4 VLPs with carbohydrate ligand. Sigmoidal curves were fit to the mean percent control 838 
binding (percent of VLP bound to ligand in the presence of antibody pretreatment compared to 839 
the amount of VLP bound in the absence of antibody pretreatment) at room temperature (Panel 840 
A) and 37
ż
C (Panel B) and the mean EC50 (ȝg/ml) titers for blockade at room temperature (Ɣ) 841 
and 37
ż
C (Ɣ) calculated and compared (Panel C). The fold change in EC50 titer was defined as 842 
the mean EC50 at 37
 ż
C compared to room temperature.   * Mean EC50 blockade titer is 843 
significantly different between room temperature and 37
o
C. Dashed line in Panel C marks the 844 
assay upper limit of detection.  Error bars represent the SEM on sigmoidal fit curves and 95% 845 
confidence intervals on Mean EC50 graphs. 846 
42 
 
 847 
Figure 3.  Access of GII.4.2002.G5 to a conserved GII.4 blockade epitope is regulated by 848 
temperature. GII.4.2002.G5 was assayed for ability to block the interaction of GII.4 VLPs with 849 
carbohydrate ligand at room temperature (Ɣ) and 37
ż
C (Ɣ). Sigmoidal curves were fit to the 850 
mean percent control binding (percent of VLP bound to ligand in the presence of antibody 851 
pretreatment compared to the amount of VLP bound in the absence of antibody pretreatment) and 852 
the mean EC50 (ȝg/ml) titer for blockade calculated. The fold change in EC50 titer was defined as 853 
the mean EC50 at 37
 ż
C compared to room temperature.   * Mean EC50 blockade titer is 854 
significantly different between room temperature and 37
o
C.  Non-blockade VLPs were assigned 855 
an EC50 of 2X the upper limit of detection for statistical analysis and denoted by a data marker 856 
on the graph above the dashed line (assay upper limit of detection) for visual comparison. Error 857 
bars represent 95% confidence intervals. 858 
 859 
Figure 4.  Antibody access to the conserved epitope is not temperature sensitive on  860 
GII.4.2009 VLPs made at lower temperature in insect cells.  Epitope A human mab (Panel 861 
A), NVB 71.4 (Panel B) and GII.4.2002.G5 (Panel C) were assayed for ability to block the 862 
interaction of GII.4.2009 VLPs produced in insect cells using a baculovirus expression system 863 
and carbohydrate ligand at room temperature (Ɣ) and 37
ż
C (Ɣ). Sigmoidal curves were fit to the 864 
mean percent control binding (percent of VLP bound to ligand in the presence of antibody 865 
pretreatment compared to the amount of VLP bound in the absence of antibody pretreatment) and 866 
the mean EC50 (ȝg/ml) titer for blockade calculated. The fold change in EC50 titer was defined as 867 
the mean EC50 at 37
 ż
C compared to room temperature.   * Mean EC50 blockade titer is 868 
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significantly different between room temperature and 37
o
C. Error bars represent 95% confidence 869 
intervals.  870 
 871 
Figure 5.  Predicting a conserved epitope. This figure shows Chain A (dark blue) and Chain B 872 
(light blue) of the protruding domain structure. The P1 subdomain is highly conserved among 873 
GII.4 epidemic strains and is hidden from the surface in the context of the VLP superstructure. 874 
The carbohydrate binding pocket (pink) is located in the P2 subdomain, which is exposed on the 875 
surface of the VLP (Panel A). A conserved region was identified on the side of the P domain 876 
dimer, distal to the binding pockets with sites of variation (red) that correlated with phenotypic 877 
differences among GII.4 VLPs (Panel B). The ERK motif (Panel C, rotated 60° 878 
counterclockwise on the X-axis compared to Panel B) is comprised of three charged amino acids 879 
that are found at positions 316, 484, and 493 (red) in the conserved region (encompassed in the 880 
red line) that is predicted to interact with NVB 71.4. Variation at position 310 (yellow) is 881 
proximal to the conserved region (Panel D) and may regulate binding to this conserved site. 882 
 883 
Figure 6.  Characterization of VLPs with substitutions in predicted conserved antibody 884 
epitopes.  Schematic of constructs (Panel A).  Particle integrity was verified by transmission 885 
electron microscope visualization (Panel B) and carbohydrate ligand (Pig Gastric Mucin type III, 886 
PGM) binding of VLPs (Panel C).  Non-PGM binding VLPs were assigned an EC50 of 2X the 887 
upper limit of detection for statistical analysis and denoted by a data marker on the graph above 888 
the dashed line (assay upper limit of detection) for visual comparison. Error bars represent 95% 889 
confidence intervals. 890 
 891 
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Figure 7.  ERK motif substitutions decrease NVB 71.4 and GII.4.2002.G5 blockade 892 
potential with little impact on blockade temperature sensitivity. NVB 71.4 (Panels A and D), 893 
GII.4.2002.G5 (Panels B and E) and NVB 71.4 Fab (Panels C and F) were assayed for ability 894 
to block carbohydrate ligand interaction of GII.4.2006 VLPs at room temperature (Ɣ) and 37
 ż
C 895 
(Ŷ) and GII.4.2006.ERK  VLPs at room temperature (Ɣ) and 37 żC (Ŷ). Sigmoidal curves were fit 896 
to the mean percent control binding (percent of VLP bound to ligand in the presence of antibody 897 
pretreatment compared to the amount of VLP bound in the absence of antibody pretreatment) and 898 
the mean EC50 (ȝg/ml) titer for blockade calculated and compared. The fold change in EC50 titer 899 
was defined as the mean EC50 at 37
 ż
C compared to room temperature. * Mean EC50 blockade 900 
titer for GII.4.2006.ERK significantly different from the mean EC50 blockade titer for GII.4.2006 901 
at the same temperature. Non-blockade VLPs were assigned an EC50 of 2X the upper limit of 902 
detection for statistical analysis and denoted by a data marker on the graph above the dashed line 903 
(assay upper limit of detection) for visual comparison. Error bars represent the SEM on 904 
sigmoidal fit curves and 95% confidence intervals on Mean EC50 graphs. 905 
 906 
Figure 8.  Predicting residues that interact with the ERK motif.  The ERK motif was mapped 907 
onto the crystal structure of GII.4.2004 to identify sites that may be interacting with the ERK 908 
motif (Panel A).  The ERK motif is highly conserved among epidemiologically important GII.4 909 
strains while residue 310 has evolved in the most recent GII.4 strains with global distribution 910 
(Panel B). 911 
 912 
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Figure 9.  Characterization of VLPs with substitutions in residue 310 and NERK.  913 
Schematic of constructs (Panel A).  Particle integrity was verified by transmission electron 914 
microscope visualization (Panel B) and carbohydrate ligand (PGM) binding of VLPs (Panel C). 915 
Dashed line marks the upper limit of detection in Panel C. Error bars represent 95% confidence 916 
intervals. 917 
 918 
Figure 10.  Residue 310 inversely modulates blockade potency and temperature sensitivity 919 
of the conserved GII.4 epitope.  GII.4.2002.G5 (Panels  A and B), and NVB 71.4 Fab 920 
fragments, and NVB 71.4 IgG (Panel B) were assayed for ability to block the interaction of 921 
VLPs with carbohydrate ligand at room temperature and (Ɣ) and 37
 ż
C (Ɣ). Sigmoidal curves 922 
were fit to the mean percent control binding (percent of VLP bound to ligand in the presence of 923 
antibody pretreatment compared to the amount of VLP bound in the absence of antibody 924 
pretreatment) and the mean EC50 (ȝg/ml) titer for blockade calculated. The fold change in 925 
potency (EC50 titer) was defined as the ratio between mutant VLPs and wildtype VLP at room 926 
temperature (Panels A and B).  The fold change in temperature sensitivity was defined as the 927 
change in ratio between mean EC50 at 37
 ż
C compared to room temperature for the mutant VLP 928 
compared to ratio at both temperatures for the wildtype VLP (Panel B).  * Mean EC50 blockade 929 
titer for mutant VLP significantly different from the mean EC50 blockade titer for wildtype VLP 930 
at the same temperature.  Error bars represent 95% confidence intervals.  Ŷ Fold increase. Ŷ Fold 931 
decrease. 932 
 933 
Figure 11.  Antibody-bound VLPs retain structural integrity. GII.4.2009 (Panel A) and 934 
GII.4.2009.NERK (Panel B) VLPs were immuno-stained with NVB 71.4 or epitope A 935 
46 
 
(GII.4.2009 only, Panel C) humabs and visualized by negative stain transmission electron 936 
microscopy. Arrows denote immuno-gold labeled VLPs. 937 
 938 
Figure 12.  Binding of NVB 71.4 does not disrupt surface epitope A topology.  Human mabs 939 
to surface epitope A or NVB 71.4 were evaluated for ability to block binding of mouse mabs to 940 
epitope A or the conserved blockade epitope in GII.4.1997 (Panel A) and GII.4.2006 (Panel B) 941 
using a BOB assay.  Sigmoidal curves were fit to the mean percent control binding (percent of 942 
mouse mab bound to VLP in the presence of human mab pretreatment compared to the amount 943 
of mouse mab bound in the absence of human mab pretreatment) and the mean EC50 (ȝg/ml) titer 944 
for blockade of binding calculated.  Ŷ EC50 > 8μg/ml, Ŷ EC50 < 1μg/ml. 945 
 946 
Figure 13.  The mapped epitopes of GII.4 noroviruses.  The previously described evolving 947 
antibody blockade epitopes A-E are shown on the surface next to the carbohydrate binding sites 948 
(pink) (Panel A).  The NERK motif is shown in red (red) and is distal to the carbohydrate 949 
binding sites (pink) (Panel B).  950 
 951 
Figure 14.  Proposed model for regulation of antibody access to the conserved GII.4 952 
blockade epitope/s by the NERK motif and VLP structural conformation.  GII.4 NoV VLPs 953 
produced in mammalian cells can exist in multiple conformations.  Two possibilities are 954 
represented here by the light and dark green VLP shading.  Antibody access to the conserved 955 
GII.4 blockade epitope is different between these states.  Antibody “locking” of the particle into 956 
an epitope accessible conformation prevents ligand binding and antibody blockade activity.  957 
Further, antibody access to the conserved GII.4 blockade epitope can be regulated by 958 
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temperature and residues outside of the antibody binding site.  Elevated temperature or a serine 959 
at residue 310 favors antibody access to the epitope and subsequently more blockade activity 960 
whereas lower temperature or an aspartic acid at position 310 restricts antibody access to the 961 
epitope resulting less blockade activity. 962 
963 
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Tables 964 
TABLE 1 Monoclonal antibody functional affinities for GII.4.2006 and GII.4.2006.ERK at 965 
room temperature and 37°C 966 
mab Temp 
(°C) 
GII.4.2006 Kd 
(nM ± SEM) 
GII.4.2006.ERK Kd 
(nM ±SEM) 
NVB 71.4 RT 0.48 ± 0.09 0.56 ± 0.01 
NVB 71.4 37 0.27 ± 0.01 0.29 ± 0.05 
GII.4.2002.G5 RT 1.0 ± 0.24 2.0 ± 0.29 
GII.4.2002.G5 37 0.57 ± 0.05 0.87 ± 0.11 
Epitope D RT 0.78 ± 0.09 0.95 ± 0.13 
Epitope D 37 0.39 ± 0.07 0.41 ± 0.05 
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